Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + enzalutamide vs enzalutamide in metastatic castration-resistant prostate cancer
2016-003092-22Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Atezolizumab + enzalutamide with Enzalutamide alone (2 arms). Primary endpoint: Overall survival. Started Mar 2017; status: completed.
02
Drugs
atezolizumabenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-003092-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003092-22.